01:58 PM EDT, 10/17/2025 (MT Newswires) -- Rani Therapeutics ( RANI ) said on Friday that it signed a collaboration and licensing agreement valued at up to $1.09 billion with Japan's Chugai Pharmaceutical to develop and commercialize its RaniPill oral delivery technology and Chugai's rare disease antibody candidate.

Shares of Rani quadrupled, as intraday trading volume rose to over 418.4 million from a daily average of about 608,000.

Artiva Biotherapeutics ( ARTV ) said late Thursday that the US Food and Drug Administration has granted a fast-track designation to AlloNK for the treatment of refractory rheumatoid arthritis in combination with rituximab and that it has prioritized the disease as the program's lead indication.

Shares soared 145% as intraday trading volume surged to more than 85.3 million from a daily average of about 408,000.

Disc Medicine's ( IRON ) shares jumped 20% amid heavy trading after the company said it has received a Commissioner's National Priority Voucher from the US Food and Drug Administration for its drug candidate bitopertin. The voucher expedites the drug review process.

Nearly 1.8 million shares traded intraday compared with a daily average of roughly 354,000.

Price: 1.95, Change: +1.48, Percent Change: +314.21